查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球药物洗脱支架市场 - 2023-2030年
市场调查报告书
商品编码
1297816

全球药物洗脱支架市场 - 2023-2030年

Global Drug Eluting Stents Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球药物洗脱支架市场在2022年达到63亿美元，预计到2030年将见证有利可图的增长，达到102亿美元。在预测期内（2023-2030年），全球药物洗脱支架市场预计将呈现6.4%的复合增长率。

近年来，随着心血管疾病发病率的增加和支架技术的进步，全球药物洗脱支架（DES）市场已大幅增长。全球药物洗脱支架市场的一些最新趋势包括对基于生物降解聚合物的DES的日益青睐，适应症的扩大，以及为个别病人定制支架。

全球药物洗脱支架（DES）市场正受到多种因素的推动，如心血管疾病发病率的增加，采用创伤性小的手术，以及人口老龄化。例如，根据美国疾病控制和预防中心（CDC）2023年的报告，2021年美国约有69.5万人死于心脏病，每五个人中就有一个死于心脏病。

市场动态

不断增长的老龄人口正在推动全球药物洗脱支架市场的增长

人口老龄化是全球药物洗脱支架行业的一个主要驱动力。例如，随着年龄的增长，个人患心血管疾病，特别是冠状动脉疾病的风险大大增加。介入心脏病学技术经常被用来治疗老年人的心血管问题。

例如，根据世界卫生组织（WHO）2022年的报告，到2030年，地球上每六个人中就有一个人是60岁或以上。在这个时间跨度内，60岁及以上的世界人口比例预计将从2020年的10亿增加到14亿。在2050年，60岁及以上人口的数量将增加两倍以上，接近21亿。

微创手术的采用正在推动全球药物洗脱支架市场的增长

采用小切口进入身体的微创技术，已经彻底改变了介入心脏病学领域，并重新定义了心血管疾病的治疗格局。药物洗脱支架，涂有药物以防止动脉再狭窄，为冠状动脉疾病提供了一个非常成功的微创治疗选择。

较小的切口和对病人解剖结构的破坏较少，使术后疼痛和插入DES的困难减少。此外，医疗技术的进步正在推动微创手术的采用，如DES的插入。基于导管的输送设备、成像模式和机器人辅助干预都极大地提高了DES手术的精确度和安全性。这些改进使医疗机构能够更准确地进行复杂的治疗，并改善病人的治疗效果。

与药物洗脱支架相关的高成本阻碍了市场的增长

药物洗脱支架的价格不断攀升，是药物洗脱支架市场进展的一个关键障碍。与普通支架相比，这些支架的成本增加是市场增长的一个重要障碍。要求越来越多地使用药物洗脱支架的法规的建立，将导致整体支架成本的大幅增加。

例如，根据国家药品定价局（NPPA）2023年3月发布的命令，由金属DES和生物可吸收血管支架或生物可降解支架组成的药物洗脱支架（DES）的上限价格已被修订为38,265卢比。这两种类型的支架在2022年4月的最高价格分别为9373卢比和34128卢比。

COVID-19影响分析

全球药物洗脱支架（DES）市场受到了COVID-19大流行病的巨大影响。由于医院专注于治疗COVID-19患者，包括DES植入在内的选择性治疗的数量减少。此外，由于旅行限制和社会疏远的努力，这一流行病减少了病人获得医疗保健的机会。这使得患者更难接受必要的治疗，如DES植入。

COVID-19的流行也提高了DES植入的成本。这是由于多种原因造成的，包括更大的PPE成本和由于感染风险增加而必须进行更复杂的手术。植入DES的费用上升，使得一些人越来越难以获得这种治疗。

尽管有COVID-19大流行的障碍，全球DES市场在未来几年可能会上升。这是因为心血管疾病，如冠状动脉疾病和周围动脉疾病正变得越来越普遍。这些疾病是导致世界各地死亡和残疾的首要原因。

俄罗斯-乌克兰冲突分析

俄乌冲突对药物洗脱支架（DES）的全球市场产生了负面影响。战争造成了全球供应链的中断，导致DES价格上涨。此外，战争还造成了经济不稳定，从而减少了对DES的需求。因此，全球DES市场的扩张速度可能比战前要慢。

战争造成了全球供应链的中断，导致DES价格上涨。这是由于DES是由一系列组件构成的，其中一些来自俄罗斯或乌克兰。例如，钯金是生产DES的一个关键部件，而俄罗斯是钯金的一个大生产国。由于这场战斗，钯的价格上升，导致DES的价格上升。

由于战争的经济不稳定，对DES的需求也下降了。这是因为当经济不稳定时，人们不太愿意花钱做冠状动脉支架等选择性手术。因此，全球药物洗脱支架市场预计将以比战争前更慢的速度扩张。市场仍有可能发展，但速度要比没有战争的时候慢一些。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按涂层分析
  • 按应用分类
  • 按终端用户分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 老龄化人口的增长
      • 采用微创手术
    • 限制因素
      • 药物洗脱支架的高成本
    • 机会
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第六章：COVID-19分析

  • 对COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：按涂层分类

  • 基于聚合物的涂层支架
  • 无聚合物涂层支架

第九章：按应用分类

  • 冠状动脉疾病
  • 周边动脉疾病

第十章：按终端用户分类

  • 医院
  • 非住院手术中心
  • 心脏中心

第十一章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第十二章 ：竞争格局

  • 竞争格局
  • 产品标杆
  • 公司份额分析
  • 主要发展和战略

第十三章 ：公司简介

  • Boston Scientific Corp.
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • Abbott Laboratories
  • Medtronic Plc
  • Biotronik Inc.
  • Johnson & Johnson
  • MicroPort Scientific Corporation
  • Cook Medical Inc.
  • Stentys S.A.
  • Biosensors International Group
  • Terumo Corp.

第十四章：附录

简介目录
Product Code: MD1116

Market Overview

The Global Drug Eluting Stents Market reached US$ 6.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 10.2 billion by 2030. The global drug eluting stents market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).

The global drug-eluting stents (DES) market has grown significantly in recent years as the prevalence of cardiovascular illnesses has increased and stent technologies have advanced. Some of the most recent trends in the globally drug-eluting stents market include the growing preference for biodegradable polymer-based DES, the expansion of indications, and customized stents for individual patients.

The global drug-eluting stents (DES) market is being pushed by multiple factors such as the increasing prevalence of cardiovascular diseases, the adoption of procedures that are less invasive, and an aging population. For instance, according to a 2023 report by the Centers for Disease Control and Prevention (CDC), heart disease accounted for approximately 695,000 deaths in the United States in 2021, accounting for one in every five deaths.

Market Dynamics

The Growing Aging Population is Propelling the Growth of the Global Drug Eluting Stents Market

The aging population is a major driver of the global drug-eluting stents industry. For example, individuals' risk of getting cardiovascular disorders, particularly coronary artery disease, increases considerably as they age. Interventional cardiology techniques are frequently used to treat cardiovascular problems in the elderly.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. In 2050, the number of persons aged 60 and up will more than treble, approaching 2.1 billion.

The Adoption of Minimally Invasive Procedures is Driving the Growth of the Global Drug Eluting Stents Market

Minimally invasive techniques, that employ small incisions to get access to the body, have revolutionized the area of interventional cardiology and are redefining the therapeutic landscape for cardiovascular diseases. Drug eluting stents, which are coated with medication to prevent the re-narrowing of arteries, provide a highly successful and minimally invasive therapy option for coronary artery disease.

Smaller incisions and less disruption to the patient's anatomy result in less post-operative pain and difficulties with DES insertion. Furthermore, advances in medical technology are driving the adoption of minimally invasive procedures such as DES insertion. Catheter-based delivery devices, imaging modalities, and robotic-assisted interventions have all increased the precision and safety of DES procedures dramatically. These improvements allow healthcare providers to undertake complex therapies with better accuracy and improve patient outcomes.

The High Cost Associated with Drug Eluting Stent is Hampering the Growth of the Market

The escalating price of drug-eluting stents is a key impediment to the drug-eluting stent market's progress. The increased cost of these stents in comparison to regular stents is a significant impediment to market growth. The establishment of regulations requiring the increasing use of drug-eluting stents would result in a large increase in overall stent costs.

For instance, according to an order issued by the National Pharmaceutical Pricing Authority (NPPA) in March 2023, the ceiling price of drug-eluting stents (DES), comprising metallic DES and bio-absorbable vascular scaffold or bio-degradable stents, has been revised to Rs 38,265. The ceiling prices for these two types of stents in April 2022 were Rs 9,373 and Rs 34,128 respectively.

COVID-19 Impact Analysis

The global drug-eluting stent (DES) market has been significantly impacted by the COVID-19 pandemic. As hospitals focused on treating COVID-19 patients, the number of elective treatments, including DES implantations, decreased. Furthermore, because to travel restrictions and social distancing efforts, the epidemic has reduced patient access to healthcare. This has made it more difficult for patients to receive necessary therapy, such as DES implantations.

The COVID-19 epidemic has also raised the cost of DES implantations. This is due to a variety of causes, including greater PPE costs and the necessity for more complex procedures due to the increased risk of infection. The rising expense of DES implantations has made this treatment increasingly difficult to get for some people.

Despite the COVID-19 pandemic's hurdles, the global DES market is likely to rise in the future years. This is because cardiovascular disorders such as coronary artery disease and peripheral artery disease are becoming more common. These diseases are the top causes of mortality and disability around the world.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is having a negative influence on the global market for drug-eluting stents (DES). The war has caused interruptions in the worldwide supply chain, resulting in higher DES prices. Furthermore, the war has created economic instability, which has reduced demand for DES. As a result, the global DES market is likely to expand at a slower rate than it did prior to the war.

The war has caused interruptions in the global supply chain, resulting in higher DES prices. This is due to the fact that DES are built from a range of components, some of which come from Russia or Ukraine. Palladium, for example, is a critical component in the production of DES, and Russia is a large producer of palladium. As a result of the battle, the price of palladium has risen, resulting in higher DES prices.

Because of the war's economic instability, demand for DES has fallen. This is because when there is economic uncertainty, people are less willing to spend money on elective operations such as coronary artery stenting. Thus, the global drug-eluting stent market is expected to expand at a slower rate than it did prior to the war. The market is still likely to develop, but at a slower rate than it would have been without the war.

Segment Analysis

The global drug eluting stents market is segmented based on coating, application, end user, and region.

The Coronary Artery Disease Segment is expected to hold a Dominant Position accounting for 74.1% of the Global Drug Eluting Stent Market over the Forecast Period

The coronary artery disease (CAD) is characterized by narrowing or blockage of the coronary arteries, which provide blood to the heart muscle. It is a prevalent cardiovascular disease that is a primary cause of morbidity and mortality worldwide. Several variables, including the high prevalence of coronary artery disease, and proven efficacy in CAD treatment, contribute to the coronary artery disease segment's dominance in the global drug eluting stent market.

Coronary artery disease (CAD) is a common disease that affects a sizable section of the world's population. The prevalence of CAD is further increased by the rising incidence of risk factors such as sedentary behavior, poor eating habits, smoking, and obesity. For instance, according to a 2023 report by the Centers for Disease Control and Prevention (CDC), about 375,476 people died from CAD in 2021 alone.

Moreover, CAD affects about 5% of persons aged 20 and over which shows how severely it affects a sizeable segment of the population. Alarmingly, in 2021, over 2 out of every 10 deaths from CAD occurred in those under the age of 65, emphasizing its effect on people who are relatively younger. Thus, owing to this reason the market for drug eluting stent will escalate at a higher CAGR over the forecast period.

Geographical Analysis

North America holds a Dominant Position in the Global Drug Eluting Stent Market.

North America is estimated to hold around 39.6% of the total market share throughout the forecast period, owing to the well-established healthcare infrastructure, favorable reimbursement policies, and presence of leading market players.

The recent collaborative efforts and agreements among companies are driving the market. For instance, in May 2023, CoSo Health and Medinol collaborated together to make EluNIR available in the United States. Medinol is renowned internationally for its experience developing ground-breaking implantable medical devices. Endovascular, a reputed distributor of peripheral and coronary devices, plays a vital role in ensuring the widespread availability of these goods.

Competitive Landscape

The major global players in the market include: Boston Scientific Corp., Abbott Laboratories, Medtronic Plc, Biotronik Inc., Johnson & Johnson, MicroPort Scientific Corporation, Cook Medical Inc., Stentys S.A., Biosensors International Group, and Terumo Corp., among others.

Why Purchase the Report?

  • To visualize the global drug eluting stents market segmentation based on the coating, application, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of drug eluting stents market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global drug eluting stents market report would provide approximately 49 tables, 53 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Coating
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Aging Population
      • 4.1.1.2. Adoption towards Minimal Invasive Procedures
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost associated with Drug Eluting Stent
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Coating

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
    • 8.1.2. Market Attractiveness Index, By Coating
  • 8.2. Polymer-based Coating Stents*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Polymer-free Coating Stents

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Coronary Artery Diseases*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Peripheral Artery Disease

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Ambulatory Surgical Centers
  • 10.4. Cardiac Centers

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. The U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. The U.K.
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Coating
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. Boston Scientific Corp.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Abbott Laboratories
  • 13.3. Medtronic Plc
  • 13.4. Biotronik Inc.
  • 13.5. Johnson & Johnson
  • 13.6. MicroPort Scientific Corporation
  • 13.7. Cook Medical Inc.
  • 13.8. Stentys S.A.
  • 13.9. Biosensors International Group
  • 13.10. Terumo Corp.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us